Biomarker Technologies Market Global Report 2026

The biomarker technologies market size has grown rapidly in recent years. It will grow from $56.62 billion in 2025 to $64.03 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases driving diagnostic demand, expansion of clinical laboratory infrastructure globally, rising adoption of molecular diagnostic testing, growth in pharmaceutical R&D investments, improved awareness of early disease detection benefits.

The biomarker technologies market size is expected to see rapid growth in the next few years. It will grow to $103.12 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expansion of precision medicine adoption in healthcare systems, rising demand for minimally invasive diagnostic solutions, increasing integration of multi omics based research approaches, growth in decentralized and point of care testing models, expansion of personalized treatment monitoring and therapy optimization. Major trends in the forecast period include rising demand for early disease detection through molecular marker based screening, expansion of preventive and proactive healthcare screening programs, increasing regulatory standardization and validation requirements in diagnostic testing, growth of large scale biobanking and centralized biological sample repositories, rising adoption of multi sample biological testing workflows integrating blood urine and saliva based diagnostics.

The increasing demand for personalized medicine is expected to drive the growth of the biomarker technologies market going forward. Personalized medicine is a healthcare approach that utilizes genetic, molecular, and individual patient-specific information to support diagnosis, treatment selection, and disease management decisions. The demand for personalized medicine is rising as pharmaceutical companies increasingly focus on developing targeted therapies that require accurate patient identification and biomarker-driven treatment strategies. Biomarker technologies enable personalized medicine by identifying measurable biological indicators that support targeted drug development, patient segmentation, and treatment optimization. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, representing a significant rise compared to six approvals in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the biomarker technologies market.

Major companies operating in the biomarker technologies market are focusing on developing advanced spatial biology technologies, such as artificial intelligence-enabled spatial biomarker analysis platforms, to enhance cancer diagnostics and translational research capabilities. Artificial intelligence-enabled spatial biomarker analysis platforms integrate tissue imaging, molecular profiling, and computational analytics to analyze biomarker expression patterns and cellular interactions within tissue samples. For instance, in April 2024, Nucleai, an Israel-based biotechnology company, launched new artificial intelligence-powered spatial biomarker advancements at the American Association for Cancer Research 2024 conference. The technology enables automated pathology analysis, combines spatial biology data with artificial intelligence models, and enhances biomarker discovery for oncology treatment development. The platform also facilitates detailed analysis of the tumor microenvironment, allowing researchers to better understand cellular interactions that impact disease progression and therapeutic response. Additionally, it supports patient stratification and predictive analytics, enabling pharmaceutical and biotechnology companies to identify appropriate patient groups and accelerate the development of personalized cancer treatments.

In July 2024, Thermo Fisher Scientific, a US-based provider of analytical instruments, acquired Olink Holding AB for $3.1 billion. Through this acquisition, Thermo Fisher Scientific aimed to enhance its proteomics and biomarker discovery capabilities by integrating Olink’s advanced protein analysis platform to expand precision medicine and translational research applications. Olink Holding AB is a Sweden-based provider of proteomics solutions and biomarker discovery technologies that support disease research, pharmaceutical development, and precision diagnostics.

Major companies operating in the biomarker technologies market report are Labcorp Holdings Incorporated, Illumina Incorporated, BioMérieux SA, Bruker Corporation, Bio-Rad Laboratories Incorporated, Exact Sciences Corporation, Bio-Techne Corporation, Myriad Genetics Incorporated, MDxHealth SA, Guardant Health Incorporated, Veracyte Incorporated, Tempus AI Incorporated, Meso Scale Diagnostics LLC, Adaptive Biotechnologies Corporation, Alamar Biosciences Incorporated, Burning Rock Biotech Limited, SOPHiA GENETICS SA, Seer Incorporated, Biomodal Limited, Thermo Fisher Scientific, F. Hoffmann-La Roche AG, QIAGEN N.V., Agilent Technologies Incorporated, Quest Diagnostics Incorporated.

North America was the dominating region in the biomarker technologies market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the biomarker technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biomarker technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.